NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV).Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=101872&from=4 CLASS PERIOD: Aug ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. ("Verve Therapeutics" or the "Company") (NASDAQ: VERV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Verve Therapeutics investors who were adversely affected by alleged securities fraud between August 9, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=101235&from=3  CLASS PER ...

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of publicly traded Verve Therapeutics, Inc. (NASDAQ: VERV) (“Verve” or the “Company”) securities between August 9, 2022 and April 1, 2024, inclusive (the “Class Period”), charging the Company and certain senior executives with violations of the federal securities laws (collectively, “Defendants”).   Verve investors have until October 28, 2024 to seek appointment as lead plaintiff of the V ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Verve Therapeutics securities during the Class Period you may be entitled to compensation without payment of ...

NEW YORK, Sept. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV).Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/verve-therapeutics-inc-loss-submission-form/?id=100744&from=4CLASS PERIOD: Augus ...

NEW YORK, Sept. 6, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024 in the securities class action first filed by the Firm.So what: ...

文章核心观点 - 公司Verve Therapeutics被指在2022年8月9日至2024年4月1日期间(即"Class Period")做出了虚假或误导性陈述,包括未充分披露Heart-1临床试验停止的具体情况,以及夸大其专有脂质纳米颗粒(LNP)递送系统的潜在效益[1][4] - 这些虚假或误导性陈述导致投资者遭受损失[4] 根据相关目录分别进行总结 案件背景 - 罗森律师事务所代表Verve Therapeutics的投资者提起集体诉讼,要求在2022年8月9日至2024年4月1日期间购买公司证券的投资者获得赔偿[1][2] - 投资者必须在2024年10月28日之前提出成为首席原告人的申请[2] 罗森律师事务所简介 - 罗森律师事务所是一家专注于证券集体诉讼和股东衍生诉讼的全球性投资者权益律师事务所[3] - 该所在证券集体诉讼领域拥有丰富的从业经验和成功案例,曾获得多项行业荣誉[3]

文章核心观点 - Verve Therapeutics公司被指控在2022年8月9日至2024年4月1日期间存在证券欺诈行为 [1][2] - 该公司未充分披露Heart-1 Phase 1b临床试验停止的具体情况 [2] - 该公司夸大了其专有脂质纳米颗粒递送系统的潜在利益 [2] 公司情况总结 - Verve Therapeutics是一家生物技术公司,专注于开发基因编辑治疗 [1] - 公司正在开发一种名为VERVE101的基因编辑药物,正在进行临床试验 [2] - 公司声称其专有脂质纳米颗粒递送系统具有潜在优势 [2] 诉讼情况总结 - 投资者起诉公司存在证券欺诈行为 [1][2] - 投资者有机会在2024年10月28日之前申请成为集体诉讼的代表原告 [2] - 如果投资者成为集体诉讼的成员,可以获得赔偿,无需支付任何费用 [3] - 律师事务所Levi & Korsinsky在证券诉讼方面有丰富经验,曾为股东赢得数亿美元赔偿 [3]

LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as le ...